Search Result

Results for "

epileptic seizures

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (2) Amino Acid Decarboxylase (1) AP-1 (1) Apoptosis (4) Bacterial (2) Calcium Channel (3) Endogenous Metabolite (2) Environmental Pollutants (1) Fungal (1) GABA Receptor (4) HBV (1) iGluR (2) mAChR (2) Mitochondrial Metabolism (3) NF-κB (1) NO Synthase (1) Parasite (1) Phosphatase (1) Potassium Channel (1) Reactive Oxygen Species (ROS) (5) Reference Standards (4) Sodium Channel (2) TRP Channel (2) TSPO (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (20)

By Targets:

5-HT Receptor (1)

Adenosine Receptor (2)

Amino Acid Decarboxylase (1)

AP-1 (1)

Apoptosis (4)

Bacterial (2)

Calcium Channel (3)

Endogenous Metabolite (2)

Environmental Pollutants (1)

Fungal (1)

GABA Receptor (4)

HBV (1)

iGluR (2)

mAChR (2)

Mitochondrial Metabolism (3)

NF-κB (1)

NO Synthase (1)

Parasite (1)

Phosphatase (1)

Potassium Channel (1)

Reactive Oxygen Species (ROS) (5)

Reference Standards (4)

Sodium Channel (2)

TRP Channel (2)

TSPO (1)

By Research Areas:

Cancer (6)

Cardiovascular Disease (3)

Infection (2)

Inflammation/Immunology (1)

Metabolic Disease (4)

Neurological Disease (20)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1502

Carboxyatractyloside tripotassium 2 Publications Verification Gummiferin tripotassium	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .

HY-N2522

Carboxyatractyloside dipotassium 2 Publications Verification Gummiferin dipotassium	Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)	Neurological Disease
Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .

HY-147423

Zandatrigine 1 Publications Verification NBI-921352; XEN901	Sodium Channel	Neurological Disease
Zandatrigine (NBI-921352; XEN901) is a selective, orally active, voltage-gated sodium channel Na_V1.6/SCN8A inhibitor that can penetrate the blood-brain barrier. Zandatrigine inhibits sodium influx by non-covalently binding to the VSD4 structure of Na_V1.6, blocking the persistent and resuscitative currents under pathological conditions. Zandatrigine can reduce neuronal hyperexcitability and reduce epileptic seizures. Zandatrigine is 134-756-fold selective for other isoforms such as Na_V1.1 and Na_V1.2, and has minimal effect on Na_V1.1 expressed by inhibitory interneurons. Zandatrigine can be used to study Na_V1.6-mediated neuroexcitability diseases such as SCN8A-related developmental epileptic encephalopathy (SCN8A-DEE) and adult focal epilepsy .

HY-103181

N6-Cyclopentyladenosine CPA; UK-80882	Adenosine Receptor Apoptosis	Cardiovascular Disease Neurological Disease Cancer
N6-Cyclopentyladenosine (CPA) is a selective Adenosine A₁ receptor agonist, with K_i values of 2.3 nM, 790 nM and 43 nM for human A₁, A_2A and A₃ receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures .

HY-160955

Z218484536	Phosphatase	Neurological Disease
Z218484536 is a selective and brain-penetrant phosphoserine phosphatase (PSPH) inhibitor. Z218484536 binds to PSPH with a K_d value of approximately 0.23 μM. Z218484536 reduces L-serine and D-serine levels in astrocytes. Z218484536 is able to suppress spontaneous epileptic seizures without causing serious side effects. Z218484536 also shows good anti-epileptic effects in the temporal lobe epilepsy (TLE) model .

HY-108234

VU 0255035 1 Publications Verification VU 255035	mAChR	Neurological Disease
VU0255035 is a highly selective and competitive M1 mAChR antagonist. VU0255035 blocks M1 mAChR signals to reduce epileptic seizures and regulate neuronal membrane potential. VU0255035 can be used in research related to central nervous system diseases, such as epilepsy, Parkinson's disease, and dystonia .

HY-N0444

Rubiadin	Reactive Oxygen Species (ROS) NF-κB HBV Apoptosis Bacterial Fungal Parasite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

HY-W014325

TRPM8 agonist WS-3 Framidice 3	TRP Channel Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
TRPM8 agonist WS-3 is an specific agonist of TRPM8 with an EC₅₀ of 3.7 μM. TRPM8 agonist WS-3 inhibits epileptic seizures through a TRPM8 dependent mechanism. TRPM8 agonist WS-3 can be used for research on epilepsy and other conditions .

HY-W023493

DL-Allylglycine 2-Aminopent-4-enoic acid	Amino Acid Decarboxylase	Neurological Disease
DL-Allylglycine (2-Aminopent-4-enoic acid) is a glutamate decarboxylase (GAD) inhibitor. DL-Allylglycine significantly increases mouse brain ornithine decarboxylase (ODC) activity and decreases S-adenosyl-L-methionine decarboxylase (SAM-DC) activity. DL-Allylglycine causes a marked decrease in brain GABA concentration. DL-Allylglycine has convulsant activity that can be used in studies to induce epileptic seizures .

HY-130325

α-Guanidinoglutaric acid	NO Synthase	Neurological Disease
α-Guanidinoglutaric acid is a guanidino compound first found in cobaltinduced epileptogenic focus tissue in the cerebral cortex of cats. α-Guanidinoglutaric acid induces epileptic seizures in rats after intraventricular administration .

HY-B1606

Chlorothymol Chlorthymol; 6-Chlorothymol	Environmental Pollutants Bacterial AP-1 GABA Receptor	Infection Neurological Disease
Chlothymol is a potent positive modulator of the GABA_A receptor subunit LGC-37, anticonvulsant, and antibacterial agent. Chlothymol inhibits Pentylenetetrazol-induced c-fos expression. Chlothymol inhibits the growth of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) strains, including LAC, with an MIC of 32 μg/mL. Chlorothymol has protective effects against epileptic seizures in various mouse models .

HY-118931

EF-1502	GABA Receptor	Neurological Disease
EF-1502 is a potent and selective GABA transporter inhibitor with GAT1 and BGT1 inhibitory activity. EF-1502 produces a synergistic anti-epileptic effect when used in combination with Tiagabine (HY-B0696), a compound used to suppress epileptic seizures. The dosing combination of EF-1502 exhibited reduced anti-epileptic efficacy and dyskinesia when used with THIP (HY-10232). The mechanism of EF-1502 differs significantly from Tiagabine, suggesting a unique role in the inhibitory strategy .

HY-175340

Kv7.2/Kv7.3 activator-3	Potassium Channel TSPO	Neurological Disease
Kv7.2/Kv7.3 activator-3 (GRT-X) is an orally active Kv7.2/Kv7.3 and TSPO activator. Kv7.2/Kv7.3 activator-3 activates Kv7.2/Kv7.3, Kv7.4, and Kv7.5 with EC₅₀ values of 0.37, 2.06, and 0.75 μM, respectively, and binds to TSPO with K_i values of 0.07 μM (rat membrane) and 4.60 μM (human U-118 MG cells). Kv7.2/Kv7.3 activator-3 prevents motor neuron degeneration in mice and humans conditioned by ALS/FTD astrocytes. Kv7.2/Kv7.3 activator-3 stimulates dorsal root ganglion axonal growth through TSPO and Kv7.2/3 activation. Kv7.2/Kv7.3 activator-3 has anti-epileptic effects in epileptic seizure models. Kv7.2/Kv7.3 activator-3 reduces pain hypersensitivity in patients with diabetic neuropathy, promotes neuronal survival and regeneration after cervical neuropathy in rats, and accelerates the recovery of normal function of sensory and motor neurons .

HY-175263

Aminochalcone 4AAF	GABA Receptor 5-HT Receptor Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
Aminochalcone 4AAF is a neuroprotective agent that exerts anxiolytic effects through GABAA and 5-HT receptors. Aminochalcone 4AAF has high selectivity for 5-HT_3A and 5-HT_2C receptors, and stimulates allosteric behavior toward the 5-HT_2A receptor. Aminochalcone 4AAF shows hypoglycemic effects and reduces the level of ROS in the liver. Aminochalcone 4AAF delays the clonic stage of the epileptic seizures . Aminochalcone 4AAF can be used in the study of anxiety, hyperglycemia, and seizures .

HY-W014325R

TRPM8 agonist WS-3 (Standard) Framidice 3 (Standard)	Reference Standards TRP Channel Endogenous Metabolite	Neurological Disease Metabolic Disease Cancer
TRPM8 agonist WS-3 (Standard) is the analytical standard of TRPM8 agonist WS-3. This product is intended for research and analytical applications. TRPM8 agonist WS-3 is an specific agonist of TRPM8 with an EC₅₀ of 3.7 μM. TRPM8 agonist WS-3 inhibits epileptic seizures through a TRPM8 dependent mechanism. TRPM8 agonist WS-3 can be used for research on epilepsy and other conditions .

HY-N2522R

Carboxyatractyloside dipotassium (Standard) Gummiferin dipotassium (Standard)	Reference Standards Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)	Neurological Disease
Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .

HY-W818693

3-Hydroxy-3-phenylpentanamide	Apoptosis	Cancer
3-Hydroxy-3-phenylpentanamide is a compound with neuroprotective activity. 3-Hydroxy-3-phenylpentanamide shows protective effects against ischemic brain injury and cerebral hemorrhage. 3-Hydroxy-3-phenylpentanamide is studied in psychiatry as a potential anxiety, depression and addiction suppressant compound. 3-Hydroxy-3-phenylpentanamide shows antitumor activity in oncology, acting by inducing apoptosis and inhibiting tumor growth. 3-Hydroxy-3-phenylpentanamide also has protective effects against epileptic seizures .

HY-174899

AMPA-IN-2	iGluR	Neurological Disease
AMPA-IN-2 is an orally active AMPA inhibitor that can cross the blood-brain barrier. AMPA-IN-2 improves epileptic seizures by inhibiting the intrinsic excitability of neurons and inhibiting the excitability of glutamatergic transmission. AMPA-IN-2 exerts anti-epileptic effects in the pentylenetetrazol (PTZ) model and can be used as a promising candidates with high broad-spectrum anti-epileptic potential .

HY-108234R

VU 0255035 (Standard) VU 255035 (Standard)	Reference Standards mAChR	Neurological Disease
VU 0255035 (Standard) is the analytical standard of VU 0255035 (HY-108234). This product is intended for research and analytical applications. VU0255035 is a highly selective and competitive M1 mAChR antagonist. VU0255035 blocks M1 mAChR signals to reduce epileptic seizures and regulate neuronal membrane potential. VU0255035 can be used in research related to central nervous system diseases, such as epilepsy, ParK_inson's disease, and dystonia .

HY-182548

BTS 72664	GABA Receptor Sodium Channel iGluR	Cardiovascular Disease Neurological Disease
BTS 72664 is a broad-spectrum, non-sedating, orally effective anticonvulsant. Its anticonvulsant effect mainly arises from enhancing GABA_A receptor (GABA_A receptor)-mediated chloride channel currents, while it exerts weak blocking effects on Na ⁺ channels (K_i = 350 μM) and NMDA receptors (NMDA receptor) (IC₅₀ = 43 μM). BTS 72664 prevents the elevation of extracellular glutamate, glycine and serine concentrations in neurons, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of epileptic seizures, and has low sedative potential. BTS 72664 can be used for the research of epilepsy, stroke and migraine .

HY-103181R

N6-Cyclopentyladenosine (Standard) CPA (Standard); UK-80882 (Standard)	Reference Standards Adenosine Receptor Apoptosis	Cardiovascular Disease Neurological Disease Cancer
N6-Cyclopentyladenosine (Standard) is the analytical standard of N6-Cyclopentyladenosine (HY-103181). This product is intended for research and analytical applications. N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with K_i values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures .

Cat. No.	Product Name	Target	Research Area

HY-W023493

DL-Allylglycine 2-Aminopent-4-enoic acid	Amino Acid Decarboxylase	Neurological Disease
DL-Allylglycine (2-Aminopent-4-enoic acid) is a glutamate decarboxylase (GAD) inhibitor. DL-Allylglycine significantly increases mouse brain ornithine decarboxylase (ODC) activity and decreases S-adenosyl-L-methionine decarboxylase (SAM-DC) activity. DL-Allylglycine causes a marked decrease in brain GABA concentration. DL-Allylglycine has convulsant activity that can be used in studies to induce epileptic seizures .

Carboxyatractyloside tripotassium 2 Publications Verification Gummiferin tripotassium	other families Classification of Application Fields Terpenoids Diterpenoids Plants Disease Research Fields Source Classification Cancer	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel
Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .

Carboxyatractyloside dipotassium 2 Publications Verification Gummiferin dipotassium	other families Classification of Application Fields Terpenoids Other Diseases Diterpenoids Plants Disease Research Fields Source Classification	Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)
Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .

Rubiadin	Quinones Structural Classification Classification of Application Fields Anthraquinones Rubiaceae Phenols Polyphenols Plants Morinda officinalis How Inflammation/Immunology Disease Research Fields Source Classification	Reactive Oxygen Species (ROS) NF-κB HBV Apoptosis Bacterial Fungal Parasite
Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .

Carboxyatractyloside dipotassium (Standard) Gummiferin dipotassium (Standard)	other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)
Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca ²⁺ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks